Howard Solomon ’52 is an attorney who began his career working for several law firms in New York City. One of his clients was Forest Laboratories, a pharmaceutical manufacturer and marketer. Ultimately, he became President and Chief Executive Officer of the Company in 1977, and he was elected Chairman and Chief Executive Officer in December 1998. He retired as CEO and President in September 2013 and served as Chairman of the Board until the company was acquired by Actavis for approximately $28 billion in July 2014. Following retirement, Mr. Solomon formed Hildred Capital Partners, a family investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an active and passively managed basis. When Mr. Solomon became CEO of Forest, its pharmaceutical business in the United States consisted of a small and unprofitable business. Mr. Solomon led the transformation of Forest into an innovative and fully integrated multi-billion dollar pharmaceutical company. In addition to building value for shareholders, Mr. Solomon also was instrumental in building an industry-leading portfolio of groundbreaking therapies and next generation pharmaceutical products, including blockbuster products such as Celexa, Lexapro, Benicar, and Namenda. Mr. Solomon is very active in supporting the performing arts, serving as a member of the Executive Committee of the Board of Directors of the Metropolitan Opera and Chairman of the Finance Committee, and as a member of the Board of the New York City Ballet, where he served as Chairman of the Board and Chief Executive officer from 1996 to 2002 and is currently a member of the Executive Committee. In addition, he is a Member Emeritus of the Board of Directors of Lincoln Center for the Performing Arts. Mr. Solomon also is a trustee of the New York Presbyterian Hospital and a past member of the Board of Cold Spring Harbor Laboratories. Mr. Solomon attended City College of New York where he graduated cum laude. He also holds a J.D. from Yale Law School, where he was an editor of the Yale Law Journal.

David F. Solomon ’92 is a partner at Hildred Capital Partners, a family investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an active and passively managed basis. Before creating Hildred, Mr. Solomon spent thirteen years at Forest Laboratories, ultimately as Senior Vice President, Corporate Development & Strategic Planning. In that capacity, Mr. Solomon was responsible for Forest’s Business Development activities, including all M&A, licensing and product acquisitions. He also had responsibility for Forest’s Alliance Management group, which managed Forest’s many collaborations, and its Strategic Planning function, which focused on the review and evaluation of novel business opportunities as well as life-cycle planning for Forest’s portfolio. In addition, Mr. Solomon managed Forest’s business outside the United States, including its European, Canadian and Latin American operations, and he was also responsible for all of the company’s Operations, including Manufacturing and Distribution, as well as its Informatics, Compliance and Quality Affairs functions. Mr. Solomon remained with Forest until the company was acquired by Actavis for approximately $28 billion in July 2014. Prior to joining Forest, Mr. Solomon practiced entertainment law at Paul, Weiss, Rifkind, Wharton & Garrison in New York. Following that, he worked as Director of Creative Affairs at Paramount Pictures in Los Angeles, overseeing development and production of feature films for the studio, and as an independent producer with Davis Entertainment, based at 20th Century Fox. Mr. Solomon also has produced the Peabody Award winning documentary film Rebirth about a group of people whose lives were dramatically impacted by September 11th, which premiered at the Sundance Film Festival in January 2011. Mr. Solomon previously served on the Board of Directors for Moksha8, a private equity backed Latin American pharmaceutical company with commercial operations in Mexico and Brazil, and also on the Board of Directors of Trevena, a public clinical stage biotech company working in the area of G protein coupled receptor targeted medicines. He also serves on the Board of Directors of Lincoln Center Theater and the Municipal Art Society and on the Executive Board of the Yale Dramat Alumni Association. Mr. Solomon has also served as a member of the Yale University Council Committee on Theater at Yale. Mr. Solomon graduated summa cum laude with a B.S. in Biology from Yale College, where he was elected to Phi Beta Kappa and received the Jonathan Edwards Fellows Prize for Academic Achievement and the Henry E. Ellsworth Prize for the most significant senior thesis in the Natural Sciences. He received his J.D. from Yale Law School, where he was a Coker Fellow and a Senior Editor of the Yale Law Journal.